Jun 4, 2025 | Press Release
Research highlights potential of EPC-002 in the treatment of solid tumors and EPC-003 for the treatment of glioblastoma LEXINGTON, Mass. and SINGAPORE, April 28, 2025 /PRNewswire/ — Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing...
Jun 4, 2025 | Press Release
Proprietary cytokine-engineered CAR-T therapy shows durable anti-tumor activity and low-dose efficacy in solid tumors LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ — Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing...
Apr 8, 2022 | Press Release
LEXINGTON, Mass.–(BUSINESS WIRE)–Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR)...
May 18, 2021 | Press Release
LEXINGTON, MA – May 18, 2021 — Elpis Biopharmaceuticals, a biopharmaceutical company developing next generation multifunctional immunotherapies to transform cancer treatment, today announced the appointment of Dennis Benjamin, Ph.D., and Rakesh Jain, Ph.D., to...
Oct 29, 2020 | Press Release
Company raises $30 Million to allocate to pre-clinical pipeline development LEXINGTON, MA – October 29, 2020 — Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics...